Tempus AI's Ambry Genetics Leads with Validated 99.5% Accurate Hereditary Cancer Risk Assessment Tool

Tempus AI Inc. (NASDAQ:TEM) is one of the best AI stocks to buy according to hedge funds. On June 25, Ambry Genetics, which is a wholly owned subsidiary of Tempus AI, announced the publication of a peer-reviewed study in the Journal of the National Comprehensive Cancer Network. The study validates the accuracy of the Ambry CARE Program (or CARE) for hereditary cancer risk assessment.

Titled “Validation of a Digital Tool that Uses National Testing Guidelines to Identify Individuals at Risk for Hereditary Cancer,” the study confirmed that the CARE program interprets NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) with a 99.5% accuracy. This reinforces CARE’s effectiveness as a digital risk assessment tool for identifying patients who could benefit from hereditary cancer-focused genetic testing and personalized care.

About 5% of individuals carry a mutation in a cancer predisposition gene without being aware of it. While NCCN Guidelines are a trusted resource for hereditary cancer testing criteria, their complexity and frequent updates can make them challenging for non-specialist clinicians and digital health tools to apply effectively. The CARE program addresses this by streamlining the hereditary cancer risk assessment process.

Tempus AI Inc. (NASDAQ:TEM) is a healthcare technology company. Ambry Genetics translates scientific research into clinically actionable test results from an understanding of the human genome and the biology behind genetic disease.

While we acknowledge the potential of TEM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.